Home › Funds › PERCEPTIVE ADVISORS LLC › INBX
PERCEPTIVE ADVISORS LLC position in INBX
INHIBRX BIOSCIENCES INC COM · Health Care
PERCEPTIVE ADVISORS LLC reported holding 1,297,763 shares of INBX (INHIBRX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$123.0M, representing 1.95% of its reported portfolio and ranking #15 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed INBX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PERCEPTIVE ADVISORS LLC's INBX position evolved
PERCEPTIVE ADVISORS LLC first disclosed a stake in INBX in Q3 2023 at 4,256,104 shares (US$78.1M). The position peaked in Q4 2023 at 4,256,104 shares, worth US$161.7M. Across 12 filings, PERCEPTIVE ADVISORS LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 1,297,763 shares valued at US$123.0M — a reduction of -144,944 shares quarter over quarter.. Notable position changes include a 75% trim in Q2 2024 (shares rose 11% over the following quarter), a 36% increase in Q3 2025 (shares rose 135% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.26M | $78.10M | New |
| Q4 2023 | 4.26M | $161.73M | Hold |
| Q1 2024 | 4.26M | $148.79M | Hold |
| Q2 2024 | 1.06M | $15.08M | Reduce |
| Q3 2024 | 1.06M | $16.66M | Hold |
| Q4 2024 | 1.06M | $16.39M | Hold |
| Q1 2025 | 1.06M | $14.89M | Hold |
| Q2 2025 | 977.89K | $13.95M | Reduce |
| Q3 2025 | 1.33M | $44.72M | Add |
| Q4 2025 | 1.45M | $114.76M | Add |
| Q1 2026 | 1.44M | $96.99M | Reduce |
| Q2 2026 | 1.30M | $122.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC COM) is a Health Care company. 43 other funds we track also report a position in INBX — the largest reported positions include Sanofi (US$109.7M), Schonfeld Strategic Advisors LLC (US$66.1M), PFM Health Sciences, LP (US$29.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- Sanofi 1.16M sh · $109.71M · Q2 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- PFM Health Sciences, LP 308.38K sh · $29.22M · Q2 2026
- Sofinnova Investments, Inc. 303.10K sh · $28.72M · Q2 2026
- Parkman Healthcare Partners LLC 256.95K sh · $24.35M · Q2 2026
- First Turn Management, LLC 164.78K sh · $15.61M · Q2 2026
- Western Standard LLC 47.00K sh · $4.45M · Q2 2026
More on PERCEPTIVE ADVISORS LLC
FAQ
How long has PERCEPTIVE ADVISORS LLC held INBX?
PERCEPTIVE ADVISORS LLC has disclosed INBX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is PERCEPTIVE ADVISORS LLC's current position in INBX?
As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 1.30M shares of INBX (INHIBRX BIOSCIENCES INC COM), valued at $122.96M, representing 1.95% of its reported portfolio and ranking #15.
Has PERCEPTIVE ADVISORS LLC been buying or selling INBX?
In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC reduced its position in INBX. The position peaked in Q4 2023 at 4.26M shares.
Which other funds hold INBX?
Other major institutional holders of INBX include Sanofi, Schonfeld Strategic Advisors LLC, PFM Health Sciences, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.